Orion's partner discontinues development of levosimendan (Simdax) in the US
Orion has been informed by Abbott, the license holder for the intravenously administered formulation of levosimendan (trade name Simdax), an Orion-originated compound for acute decompensated heart failure, that Abbott has decided not to continue the development program for the product in the US, because it would not be commercially reasonable. Accordingly, the considered additional Phase 3 studies will not be conducted by Abbott. Abbott continues to assess feedback from discussions with European authorities.
Simdax will remain available in the markets where it already has been approved. The product has marketing authorisations or submitted applications in more than 40 countries.
Under a renewed licensing agreement concluded in April 2004, Abbott took over the development programme of the intravenously administered formulation of levosimendan and received also extended marketing rights to the product.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.